

## Adalimumab (Powder)

Cat. No.:	HY-P9S0009
CAS No.:	331731-18-1
Target:	Bacterial; TNF Receptor
Pathway:	Anti-infection; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Adalimumab (Powder) is a human monoclonal IgG1 antibody targeting tumour necrosis factor $\alpha$ (TNF- $\alpha$ ) <sup>[1][2]</sup> .
<b>In Vitro</b>	Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	The elimination half-life ( $t_{1/2}$ ) of Adalimumab is long (~20 days) <sup>[1]</sup> . The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr <sup>-/-</sup> mice <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. *Br J Clin Pharmacol*. 2015 Feb;79(2):286-97.
- [2]. Oberoi R, et al. Targeting Tumor Necrosis Factor- $\alpha$  with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. *PLoS One*. 2016 Jul 28;11(7):e0160145.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA